Brief: Verve Therapeutics Highlights Preclinical Data Supporting Nomination Of Verve-201 ANGPTl3 Product Candidate

Verve Therapeutics

22/08/2022 12:44

Aug 22 (Reuters) - Verve Therapeutics Inc  VERV.O :
    * VERVE THERAPEUTICS HIGHLIGHTS PRECLINICAL DATA SUPPORTING
NOMINATION OF VERVE-201 ANGPTL3 PRODUCT CANDIDATE AT THE
EUROPEAN SOCIETY OF CARDIOLOGY 2022 CONGRESS

Source text for Eikon:  ID:nGNX4rDJQ4 
Further company coverage:  VERV.O 

 ((Reuters.Briefs@thomsonreuters.com;))